OPTIMA-3, 4: Antithrombotic Therapy in ACS with AF

Phase 4, randomised, open-label trial of warfarin, dabigatran, clopidogrel, ticagrelor and aspirin in acute coronary syndrome (ACS) and Atrial fibrillation (AFib) (4 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Primary endpoint of OPTIMA-3: Composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic thromboembolism and unplanned revascularization at 12 months, Primary safety endpoint of OPTIMA-4: ISTH major bleeding or CRNMB at 12 months and 1 more. Status: unknown.